Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 559

Sort by

Sort Order Select

Journal Articles

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/ PD-L1/PD-L2 alterations

Marthe Minderman, Avital Amir, Willem Kraan, Esther J. M. Schilder-Tol, Monique E. C. M. Oud, Cornelis G. Scheepstra, Arnold L. Noorduyn, Philip M. Kluin, Marie José Kersten, Marcel Spaargaren, Steven T. Pals

Blood (2021) 138 (13): 1194–1197.

https://doi.org/10.1182/blood.2021011366

Published: 2021

Includes: Supplemental data

Journal Articles

Live or die: PD-L1 delays neutrophil apoptosis

Jamel El-Benna, Pham My-Chan Dang

Blood (2021) 138 (9): 744–746.

https://doi.org/10.1182/blood.2021012186

Published: 2021

Journal Articles

Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis

Jia-feng Wang, Yun-peng Wang, Jian Xie, Zhen-zhen Zhao, Sahil Gupta, Yu Guo, Song-hui Jia, Jean Parodo, John C. Marshall, Xiao-ming Deng

Blood (2021) 138 (9): 806–810.

https://doi.org/10.1182/blood.2020009417

Published: 2021

Includes: Supplemental data

Journal Articles

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Blood (2021) 137 (20): 2785–2799.

https://doi.org/10.1182/blood.2020005244

Published: 2021

Includes: Supplemental data

Journal Articles

Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Qingxiao Song, Xiaoning Wang, Xiwei Wu, Hanjun Qin, Yingfei Li, Arthur D. Riggs, Paul J. Martin, Yuan-Zhong Chen, Defu Zeng

Blood (2021) 137 (16): 2243–2255.

https://doi.org/10.1182/blood.2020006345

Published: 2021

Includes: Supplemental data

Journal Articles

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Blood (2021) 137 (11): 1491–1502.

https://doi.org/10.1182/blood.2020007245

Published: 2021

Includes: Supplemental data

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

Alexandre S. Cristino, Jamie Nourse, Rachael A. West, Muhammed Bilal Sabdia, Soi C. Law, Jay Gunawardana, Frank Vari, Sally Mujaj, Gayathri Thillaiyampalam, Cameron Snell, Madeline Gough, Colm Keane, Maher K. Gandhi

Blood (2019) 134 (25): 2261–2270.

https://doi.org/10.1182/blood.2019000889

Published: 2019

Includes: Supplemental data

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Microrna-31 Regulates T-Cell Metabolism Via HIF1α and Promotes Effector Function

Yongxia Wu, PhD MD, Mengmeng Zhang, MD, David Bastian, Mohammed Hanief Sofi, PhD MS, Steven Douglas Schutt, BS, Hee-Jin Choi, PhD, Corey Mealer, Hung D Nguyen, PhD, Linlu Tian, Xue-Zhong Yu, MD MS

Blood (2019) 134 (Supplement_1): 623.

https://doi.org/10.1182/blood-2019-131587

Published: 2019

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas

Xianhuo Wang, Xuhan Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Kai Fu, MD PhD, Huilai Zhang

Blood (2019) 134 (Supplement_1): 5231.

https://doi.org/10.1182/blood-2019-124266

Published: 2019

Journal Articles

May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma?

Ombretta Annibali, Antonella Bianchi, Alba Grifoni, Valeria Tomarchio, Mariantonietta Tafuri, MD, Martina Verri, Giuseppe Avvisati, MD, Anna Crescenzi

Blood (2019) 134 (Supplement_1): 5235.

https://doi.org/10.1182/blood-2019-130794

Published: 2019

Journal Articles

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ulrich Jaeger, MD, Nina Worel, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD, Isabelle Fleury, MD, Peter Borchmann, MD, Jufen Chu, PhD, Ahmed M Abdelhady, PhD, Alessandra Forcina, MD, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5325.

https://doi.org/10.1182/blood-2019-129120

Published: 2019

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): SCI-8.

https://doi.org/10.1182/blood-2019-121284

Published: 2019

Journal Articles

PD-L1 Expression in Patients with Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Its Correlation with Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1)

Inju Cho, MD PhD, Seok Jin Kim, MD PhD, Hansang Lee, MD, Young Hyeh Ko, MD

Blood (2019) 134 (Supplement_1): 1601.

https://doi.org/10.1182/blood-2019-123311

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/ PD-L1/PD-L2 alterations

Live or die: PD-L1 delays neutrophil apoptosis

Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Immune escape mechanisms for TCRLBCL

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Microrna-31 Regulates T-Cell Metabolism Via HIF1α and Promotes Effector Function

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas

May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma?

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

PD-L1 Expression in Patients with Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Its Correlation with Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only